for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Frequency Therapeutics Inc

FREQ.O

Latest Trade

15.74USD

Change

0.37(+2.41%)

Volume

215,130

Today's Range

14.98

 - 

16.30

52 Week Range

11.17

 - 

16.42

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
15.37
Open
15.29
Volume
215,130
3M AVG Volume
--
Today's High
16.30
Today's Low
14.98
52 Week High
16.42
52 Week Low
11.17
Shares Out (MIL)
30.45
Market Cap (MIL)
479.35
Forward P/E
-17.49
Dividend (Yield %)
--

Latest Developments

More

Perceptive Advisors Reports 9.96% Passive Stake In Frequency Therapeutics As Of Oct 7

Frequency Therapeutics Announced That FDA Granted Fast Track Designation For FX-322

Frequency Therapeutics Filed Restated Certificate With Secretary Of State Of State Of Delaware

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Frequency Therapeutics Inc

Frequency Therapeutics Inc. is a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair and reverse damage caused by a broad range of degenerative diseases. It is a progenitor cell activation (PCA) regeneration company, which is focused on developing small molecule drugs that activate progenitor cells within the body to restore healthy tissue. It uses its PCA technology to develop a pipeline of progenitor cell activators. It focuses on various therapeutic areas, such as hearing loss (sensorineural hearing loss- SNHL), skin and bone disorders, muscle regeneration, and gastrointestinal tract diseases. Its pipeline program are FX-322, which activates the regrowth of sensory cells in the inner ear to treat chronic noise induced hearing loss; and Multiple sclerosis (MS). It has initiated a discovery program in MS after identifying MS as a degenerative disease that has the potential to be treated with small molecules that activate progenitor cells.

Industry

Biotechnology & Drugs

Contact Info

19 Presidential Way Ste 203

+1.781.3154600

http://www.frequencytx.com/

Executive Leadership

Marc A. Cohen

Chairman of the Board

David L. Lucchino

President, Chief Executive Officer, Co-Founder, Director

Christopher R Loose

Co-Founder, Chief Scientific Officer

William J. Mclean

Co-Founder, Vice President - Biology and Regenerative Medicine

Michael Jirousek

Chief Operating Officer

Key Stats

2.00 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019(E)

0.0K
EPS (USD)

2019(E)

-0.900
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

Biotechnology firm ADC pulls listing amid latest IPO market jitters

Biotechnology company ADC Therapeutics SA <ADCT.N> postponed its planned $200 million U.S. initial public offering on Wednesday, citing adverse market conditions as it became the third company to pull a planned IPO in recent days.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up